Olivier Charmeil - Sanofi Insider

SNYNF -- USA Stock  

USD 87.10  1.65  1.93%

  President
Mr. Olivier Charmeil has served as Executive Vice President General Medicines Emerging Markets Member of the Executive Committee of Sanofi S.A. since June 2016. Prior to that, he was Executive Vice President Vaccines, Member of the Executive Committee and Global Leadership Team of the Company. He joined the Company as Senior Vice President Pharmaceutical Operations in AsiaPacific Region on February 1, 2006, the function he held until January 1, 2008, when he became appointed Senior Vice President Pharmaceutical Operations in Asia Pacific Region and Japan for over one year, until February 2009. From then to January 1, 2011, he served as Senior Vice President AsiaPacific Japan Vaccines, Member of the Management Committee of the Company. From 1989 to 1994, he worked in the Mergers and Acquisitions department of Banque de lUnion Europeenne. He joined Sanofi Pharma in 1994 as Head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer for SanofiSynthelabo in 1999 and Attache to the Chairman, JeanFrancois Dehecq, in 2000, before being appointed as Vice President of Development within the SanofiSynthelabo International Operations Division, where he was responsible for China and support functions. In 2003, Mr. Charmeil was appointed Chairman and Chief Executive Officer of SanofiSynthelabo France, before taking the post of Senior Vice President of Business Management and Support within the Pharmaceutical Operations Division. Mr. Charmeil obtained a degree from the Hautes etudes commerciales and from the Institut dEtudes Politiques de Paris.
Age: 54  President Since 2016      
33 1 53 77 40 00  http://www.sanofi.com

Management Efficiency

The company has return on total asset (ROA) of 3.78 % which means that it generated profit of $3.78 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 5.91 % meaning that it generated $5.91 on every $100 dollars invested by stockholders.
The company has accumulated 33.72 B in total debt with debt to equity ratio (D/E) of 51.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sanofi has Current Ratio of 1.25 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Darren CarrollEli Lilly and Company
2015
Iskra ReicAstraZeneca PLC
2017
Leigh PuseyEli Lilly and Company
2017
Myles ONeillEli Lilly and Company
2018
Jennifer BrendeltoBayer Aktiengesellschaft
2017
Paul HudsonAstraZeneca PLC
2013
Mark FishmanNovartis AG
2002
Bill LouvGlaxoSmithKline plc
2013
Luc DebruyneGlaxoSmithKline plc
2016
Susan MahonyEli Lilly and Company
2011
Ruud DobberAstraZeneca PLC
2016
Abbas HussainGlaxoSmithKline plc
2014
James BradnerNovartis AG
2016
Luke MielsAstraZeneca PLC
2014
Regis SimardGlaxoSmithKline plc
2018
Sean BohenAstraZeneca PLC
2015
Johna NortonEli Lilly and Company
2017
Christi ShawEli Lilly and Company
2017
Fionnuala WalshEli Lilly and Company
2007
Enrique ConternoEli Lilly and Company
2017
Alfonso ZuluetaEli Lilly and Company
2017

Entity Summary

It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1 Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi is traded on OTC Market in USA.Sanofi (SNYNF) is traded on OTC Market in USA. It is located in 54, Rue La Bo?tie and employs 106,566 people.

Sanofi Leadership Team

Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
Emmanuel Babeau, Independent Director
Claudie Haignere, Independent Director
Olivier Brandicourt, CEO, Director and Member of Strategy Committee
Pascale Witz, Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team
Serge Weinberg, Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee
Suresh Kumar, Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team
Kathleen Tregoning, Executive Vice President External Affairs; Member of the Executive Committee
Sebastien Martel, Vice President - Investor Relations and Member of the Global Leadership Team
William Sibold, Executive Vice President Sanofi Genzyme; Member of the Executive Committee
Peter Guenter, Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team
Fabienne Lecorvaisier, Director
George Grofik, Vice President of Investor Relations
Karen Linehan, Member of the Executive Board, Member of the Management Board, Senior Vice President General Counsel
David Loew, Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe
Muzammil Mansuri, Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team
Klaus Pohle, Independent Director
John Reed, President - Global Research & Development, Member of the Executive Committee
Diane Souza, Independent Director
Bernard Charles, Independent Director
Carole Piwnica, Independent Director
Elias Zerhouni, President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team
Ameet Nathwani, Executive Vice President Group Chief Medical Officer, Member of the Executive Committee
Philippe Luscan, Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team
Roberto Pucci, Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team
DavidAlexandre Gros, Executive Vice President Chief Strategy Officer and Member of the Executive Committee
Olivier Charmeil, Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team
Melanie Lee, Independent Director
Igor Landau, Director
Patrick Kron, Independent Director
Stefan Oelrich, Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee
Bonnie Bassler, Director
Thomas Suedhof, Independent Director
Laurent Attal, Director
JeanRene Fourtou, Independent Director
Gerard Kemmel, Independent Director
SuetFern Lee, Independent Director
Carsten Hellmann, Executive Vice President - Animal Health and Member of the Global Leadership Team
David Meeker, Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team
Christian Mulliez, Director
Robert Castaigne, Independent Director
Alan Main, Executive Vice President Consumer Healthcare; Member of the Executive Committee
Suet Lee, Independent Director
Jerome Contamine, Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team
Uwe Bicker, Independent Director

Stock Performance Indicators

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Price Transformation
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
few hours ago
Traded for 156.0
CRM   
Purchased a lot of shares of
few hours ago
Traded for 156.0
F   
Purchased over 300 shares of
few hours ago
Traded for 9.81
C   
Purchased over 40 shares of
few hours ago
Traded for 74.735
GM   
Purchased over 70 shares of
few hours ago
Traded for 36.08
Also please take a look at World Market Map. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Search macroaxis.com